ArticleEClinicalMedicine2021

A randomised, placebo-controlled phase 3 study to evaluate the efficacy and safety of ASP0113, a DNA-based CMV vaccine, in seropositive allogeneic haematopoietic cell transplant recipients.

Per Ljungman et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.